Literature DB >> 20456339

Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry.

Gerard P McVey1, Sean McPhail, Sarah Fowler, Gregor McIntosh, David Gillatt, Chris C Parker.   

Abstract

OBJECTIVE: to assess the patterns of care for low-risk localized prostate cancer. Management of this condition is highly controversial, with a range of treatment options, but there are no published UK data.
METHODS: data from the British Association of Urological Surgeons (BAUS) Cancer Registry were linked to the UK Association of Cancer registries postcode directory. The demographic and clinical characteristics, and the initial management of men diagnosed with low-risk localized prostate cancer in the UK between 2000 and 2006 were analysed.
RESULTS: In all, 43,322 cases of localized prostate cancer were recorded in the BAUS Registry between 2000 and 2006, of which 8861 (20%) met the criteria for low-risk disease. The proportion classified as low risk ranged from 16% in 2000 to 21% in 2006. The proportion of men with low-risk disease opting for 'watchful waiting' increased from 0% to 39% over the same period. Treatment choice was associated with socio-economic status. For example, radical prostatectomy was chosen by 34% of patients in the most affluent quintile, compared with 19% in the most deprived quintile (P= 0.01).
CONCLUSION: the management of low-risk localized prostate cancer in the UK has changed markedly in recent years, and contrasts with that in the USA. The association observed between socio-economic status and choice of treatment deserves further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456339     DOI: 10.1111/j.1464-410X.2010.09288.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  17 in total

Review 1.  Management of low (favourable)-risk prostate cancer.

Authors:  H Ballentine Carter
Journal:  BJU Int       Date:  2011-12       Impact factor: 5.588

Review 2.  Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Authors:  H Ballentine Carter
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

3.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

4.  PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.

Authors:  Francesco Cantiello; Giorgio Ivan Russo; Antonio Cicione; Matteo Ferro; Sebastiano Cimino; Vincenzo Favilla; Sisto Perdonà; Ottavio De Cobelli; Carlo Magno; Giuseppe Morgia; Rocco Damiano
Journal:  World J Urol       Date:  2015-07-21       Impact factor: 4.226

Review 5.  Can we deliver randomized trials of focal therapy in prostate cancer?

Authors:  Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-04-22       Impact factor: 66.675

6.  The change of prostate cancer treatment in Korea: 5 year analysis of a single institution.

Authors:  Dong Hoon Lee; Ha Bum Jung; Mun Su Chung; Seung Hwan Lee; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

7.  Five-year nationwide follow-up study of active surveillance for prostate cancer.

Authors:  Stacy Loeb; Yasin Folkvaljon; Danil V Makarov; Ola Bratt; Anna Bill-Axelson; Pär Stattin
Journal:  Eur Urol       Date:  2014-06-30       Impact factor: 20.096

8.  Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

Authors:  Jinping Xu; Anne Victoria Neale; Rhonda K Dailey; Susan Eggly; Kendra L Schwartz
Journal:  J Am Board Fam Med       Date:  2012 Nov-Dec       Impact factor: 2.657

9.  Prostate cancer: Time for active surveillance of intermediate-risk disease?

Authors:  Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2012-11-13       Impact factor: 14.432

Review 10.  Active surveillance for prostate cancer: a narrative review of clinical guidelines.

Authors:  Sophie M Bruinsma; Chris H Bangma; Peter R Carroll; Michael S Leapman; Antti Rannikko; Neophytos Petrides; Mahesha Weerakoon; Leonard P Bokhorst; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-01-27       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.